🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Tempus AI director Theodore Leonsis sells $16.5 million in stock

Published 12/13/2024, 06:57 PM
TEM
-

Theodore Leonsis, a director at Tempus AI, Inc. (NASDAQ:TEM), recently sold a significant portion of his holdings in the company. The transaction comes as the stock has fallen nearly 19% over the past week, according to InvestingPro data. According to a recent filing, Leonsis sold 400,000 shares of Tempus AI's Class A Common Stock, generating approximately $16.5 million. The sales were executed at prices ranging from $40.73 to $41.60 per share in the $7.32 billion market cap company.

In addition to the sales, Leonsis also reported the acquisition of 210,000 shares through the exercise of stock options at a price of $0.8542 per share. This transaction resulted in a total value of $179,382.

The transactions were carried out indirectly through Revolution Growth III, LP and Revolution Growth Management Company, Inc., entities associated with the reporting person. Following these transactions, Leonsis continues to hold a substantial number of shares in Tempus AI.

In other recent news, Tempus AI has been in the spotlight due to a series of significant developments. Following the company's recent earnings report, Piper Sandler increased the stock's price target from $40 to $70, but maintained a Neutral rating. Meanwhile, Stifel downgraded the stock from Buy to Hold, but raised the price target to $65. Needham also raised its stock price target to $56, maintaining a Buy rating.

Tempus AI's acquisition of genetics firm Ambry has been viewed as a strategic move that could introduce immediate genomics capabilities and lead to significant opportunities in data and applications over time. The company has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development, granting Avacta access to Tempus's comprehensive multimodal datasets.

Furthermore, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at a higher risk of atrial fibrillation/flutter, has recently received FDA clearance. These are some of the recent developments that have been shaping Tempus AI's trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.